← Back to patent-cliff list
Cabazitaxel
Tier C — Watch / tradeCabazitaxel
Sanofi
Originator
2010
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Tubulin
Brand：Jevtana
Indications (approved)：Prostate cancer
Regional status
US
Approved
2010-06-17
EU
Approved
2011-03-17
China
Phase II
2018-10-08
Japan
Approved
2014-07-04
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cabazitaxel?
Approved indications include: Prostate cancer.
When does the Cabazitaxel patent expire?
No public expiry year is available for Cabazitaxel yet; this page updates once verified.
How do I get a quote for Cabazitaxel intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27